Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;5(Suppl 4):e000796.
doi: 10.1136/esmoopen-2020-000796.

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer

Nuria Mederos  1 , Alex Friedlaender  2 , Solange Peters  3 , Alfredo Addeo  2
Affiliations
Review

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer

Nuria Mederos et al. ESMO Open. 2020 Nov.

Abstract

Lung cancer remains the leading cause of cancer-related deaths worldwide in women and men. In incidence, lung cancer ranks second, surpassed by breast cancer in women and prostate cancer in men. However, the historical differences in mortality and incidence rate between both sexes have changed in the last years. In the last decades, we have also witnessed an increased number of lung cancer in female never-smokers. These disparities have grown our interest in studying the impact of the gender and sex in the presentation of lung cancer. The aetiology is yet to be fully elucidated, but the data are clear so far: there is a growing divide between lung cancer presentation in women and men that will change our management and study of lung cancer. This article aims to review the sex and gender differences in lung cancer.

Keywords: gender; lung cancer; sex.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NM: declare no competing interests. AF: personal fees from BMS, Roche, Pfizer, Astellas, during the conduct of the Study. SP: has received education grants, provided consultation, attended advisory boards, and/or provided lectures for: Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Incyte, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda, from whom she has received honoraria. AA: personal fees from BMS, Astrazeneca, Roche, Pfizer, MSD, Boehringer, during the conduct of the study.

References

    1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019;85. 10.5334/aogh.2419. [Epub ahead of print: 22 Jan 2019]. - DOI - PMC - PubMed
    1. Carioli G, Bertuccio P, Boffetta P, et al. . European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol 2020;31:650–8. 10.1016/j.annonc.2020.02.009 - DOI - PubMed
    1. NIH Annual report to the nation: cancer death rates continue to decline, 2020.
    1. Jemal A, Center MM, DeSantis C, et al. . Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893–907. 10.1158/1055-9965.EPI-10-0437 - DOI - PubMed
    1. Davis A, King L. Gendered perspectives on men's changing familial roles in postwar England, c.1950-1990. Gend Hist 2018;30:70–92. 10.1111/1468-0424.12333 - DOI - PMC - PubMed